|
|
Home | Submit Press Release | Advertise | Submit Website
(CityRegions.Com, April 20, 2018 ) Worldwide Systemic Sclerosis (Scleroderma) Industry Report 2018 is an expert and inside and out investigation on the present condition of the Systemic Sclerosis (Scleroderma) Industry. The report gives a fundamental review of the business including definitions, characterizations, applications and industry chain structure. The Systemic Sclerosis (Scleroderma) showcase investigation is accommodated the universal markets including advancement patterns, aggressive scene examination, and key locales improvement status. The report also presents forecasts for Systemic Sclerosis (Scleroderma) Market investments from 2018 till 2025.
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2017, provides an overview of the Systemic Sclerosis (Scleroderma) (Immunology) pipeline landscape.
Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pains, joint pain and swelling, ulcers occurring on fingertips, bloating of the tummy and diarrhea or constipation. Treatment includes antibiotic, pain relievers and immunosuppressant.
Ask for free Sample Report@ http://orbisresearch.com/contacts/request-sample/358040
Report Highlights:
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 14, 5, 22 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.
Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Click here to get discount@ http://orbisresearch.com/contacts/discount/358040
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma) (Immunology).
- The pipeline guide reviews pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Systemic Sclerosis (Scleroderma) (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Systemic Sclerosis (Scleroderma) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology)
Reasons to buy
Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology).
Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) (Immunology) pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned:
Allergan Plc
AnaMar AB
Angion Biomedica Corp
arGentis Pharmaceuticals LLC
Bayer AG
Biogen Inc
BLR Bio LLC
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Covis Pharmaceuticals Inc
CSL Ltd
Cumberland Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
Fibrocell Science Inc
GenKyoTex SA
Gilead Sciences Inc
GlaxoSmithKline Plc
iBio Inc
Inventiva
Leadiant Biosciences Inc
MedImmune LLC
Patagonia Pharmaceuticals LLC
PDX Pharmaceuticals LLC
Peptinov SAS
ProMetic Life Sciences Inc
Ribomic Inc
Samumed LLC
Sanofi
Seattle Genetics Inc
Stemline Therapeutics Inc
Stratatech Corp
Vicore Pharma AB
viDA Therapeutics Inc
VivaCell Biotechnology Espana SL
Some Major Point From Table of Content
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Systemic Sclerosis (Scleroderma) - Overview 8
Systemic Sclerosis (Scleroderma) - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 18
Systemic Sclerosis (Scleroderma) - Therapeutics Assessment 19
12 Marketing Strategy Analysis, Distributors/Traders
13 Market Effect Factors Analysis
14 Global Patient Engagement Solutions Market Forecast (2017-2022)
15 Research Findings and Conclusion
16 Appendix
Browse Complete Report wit table of content and list of figures@ http://www.orbisresearch.com/reports/index/systemic-sclerosis-scleroderma-pipeline-review-h2-2017
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Us:
Hector Costello
Senior Manager Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas - 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
For More PRs: http://orbisnewsrelease.com
Follow Us on LinkedIn: https://www.linkedin.com/company/orbis-research
Follow us on Twitter: https://twitter.com/orbisresearch
Orbis Research
Hector Costello
+1 (214) 884-6817
sales@orbisresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
